Enterokinase,Recombinant,Expressed in E.coli大腸桿菌表達(dá)重組腸激酶(不帶標(biāo)簽)注意事項1.本產(chǎn)品所講述的緩沖體系需要自行配置,。2.不建議37℃條件下酶切，可能會有非特異性酶切出現(xiàn),。3.在＞200mM咪唑,，或＞200mMNaCl,，或＞5%甘油,，酶切會受到影響,。如果樣品溶液中含有上述成分的一種或多種，為獲得理想的酶切結(jié)果,，請先將樣品透析到25mMTris-HCl8.0緩沖液中,，然后再進(jìn)行酶切實驗；若不方便透析,，可將樣品稀釋到咪唑含量在100mM以下,，NaCl濃度在50mM以下，甘油濃度小于5%以下進(jìn)行酶切,，酶的用量與蛋白比例不變,；若干擾因素很多，且不便去除,，需要適當(dāng)增加酶量或延長酶切時間,，有助于得到理想的酶切效果。4.磷酸鹽對Enterokinase有很強(qiáng)的抑制作用,，痕量的磷酸鹽都會嚴(yán)重影響Enterokinase的活性,，因此在酶切體系內(nèi)不能存在磷酸鹽。5.本品是具有高酶活力重組腸激酶,，切割蛋白使用量少,，可不考慮除去。后續(xù)如需去除重組腸激酶,，可用陰離子交換樹脂（如DEAE-FF）對其進(jìn)行洗脫,。推薦洗脫條件如下：平衡緩沖液：25mMTris-HClpH8.0洗脫緩沖液：25mMTris-HClpH8.0，含100mMNaCl6.蛋白酶切效果不好,，可適當(dāng)增加酶量,，或適當(dāng)延長酶切時間。甲磺酸達(dá)比加群酯是一種抗凝藥,，通過競爭結(jié)合凝血酶的纖維蛋白特異結(jié)合位點,，從而抑制血栓的形成。Recombinant Human OPG-Fc

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Mouse CD24 Protein,mFc Tag通過泛素-蛋白體途徑(UPP)中的酶與底物蛋白共價連接,，并在26S蛋白體降解ATP依賴的細(xì)胞蛋白中發(fā)揮主要作用,。

Recombinant Biotinylated Human KIR2DL1 Protein,His-Avi Tag性能參數(shù)分子別名（Synonyms）CD158A;CD158Ankat1;cl-42表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanKIR2DL1ProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsHis22-Arg242.[Accession|P43626]分子量大小（MolecularWeight）TheproteinhasapredictedMWof27.1kDa.Duetoglycosylation,theproteinmigratesto48-60kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.

Coronavirusesarecommonlycomprisedoffourstructuralproteins:Spikeprotein(S),Envelopeprotein(E),Membraneprotein(M)andNucleocapsidprotein(N).TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheSproteinishomotrimeric,witheach~180-kDamonomerconsistingoftwosubunits,S1andS2.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).產(chǎn)品性質(zhì)別名SproteinRBD;SglycoproteinRBD;SpikeproteinRBDAccessionQHD43416.1表達(dá)區(qū)間及表達(dá)系統(tǒng)RecombinantSARS-CoV-2SpikeRBD(OmicronBA.4/BA.5/BA.5.1.3/BA.5.2)ProteinisexpressedfromExpi293withHistagattheC-terminal.ItcontainsArg319-Phe541(G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,L452R,S477N,T478K,E484A,F486V,Q498R,N501Y,Y505H).PreScission Protease是一種由人鼻病毒14型的3C蛋白酶（human rhinovirus）和GST組成的融合蛋白,。

SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.FGF-18與FGF R2C,，F(xiàn)GF R3C以及高爾基蛋白GLG1結(jié)合，并誘導(dǎo)星形膠質(zhì)細(xì)胞和小膠質(zhì)細(xì)胞,。Recombinant Mouse sTNF RI/TNFRSF1A

在體內(nèi),，活化的X因子（Factor Xa）切割凝血酶原,，釋放出活性肽并將凝血酶切割成具有催化活性的α-凝血酶。Recombinant Human OPG-Fc

Recombinant Biotinylated Human ENPP-3 Protein,His-Avi Tag性能參數(shù)分子別名（Synonyms）NPP3;E-NPP3;PD-Ibeta表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanENPP-3ProteinisexpressedfromHEK293withHistagandAvitagattheN-Terminus.ItcontainsLeu48-Ile875.[Accession|O14638]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof99.97kDa.Duetoglycosylation,theproteinmigratesto110-130kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.3-6months,-85~-65℃understerileconditionsafterreconstitution.Recombinant Human OPG-Fc

浦斯瑞（上海）生物醫(yī)藥有限公司是一家有著先進(jìn)的發(fā)展理念,，先進(jìn)的管理經(jīng)驗，在發(fā)展過程中不斷完善自己,，要求自己,，不斷創(chuàng)新，時刻準(zhǔn)備著迎接更多挑戰(zhàn)的活力公司,，在江蘇省等地區(qū)的化工中匯聚了大量的人脈以及**,，在業(yè)界也收獲了很多良好的評價，這些都源自于自身的努力和大家共同進(jìn)步的結(jié)果,，這些評價對我們而言是比較好的前進(jìn)動力,，也促使我們在以后的道路上保持奮發(fā)圖強(qiáng)、一往無前的進(jìn)取創(chuàng)新精神,，努力把公司發(fā)展戰(zhàn)略推向一個新高度,，在全體員工共同努力之下，全力拼搏將共同浦斯瑞（上海）生物醫(yī)藥供應(yīng)和您一起攜手走向更好的未來,，創(chuàng)造更有價值的產(chǎn)品,，我們將以更好的狀態(tài)，更認(rèn)真的態(tài)度,，更飽滿的精力去創(chuàng)造,，去拼搏，去努力,，讓我們一起更好更快的成長,！